
CBT Pharmaceuticals has dosed the first participant in its Phase 1/2 clinical trial assessing the safety and tolerability of CBT-101, in combination with PD-1 inhibitors, in advanced or metastatic hepatocellular carcinoma (HCC) and renal cell carcinoma (RCC).
In adults, HCC is the most common type of primary liver cancer, and RCC is the most common type of primary kidney cancer.
This marks the beginning of the APOLLO series of oncology clinical trials program. The plan will be carried out by CBT to evaluate if CBT-101 works in combination with other molecular agents to improve single agent immunotherapy response rates, and subsequently contributes to cancer treatment.
“Initiating our APOLLO Oncology Clinical Trials Program and dosing the first patient is a major milestone for CBT as we advance our mission to improve the lives of cancer patients through combination treatment regimens,” Sanjeev Redkar, PhD, co-founder, president and CEO of CBT Pharmaceuticals, said in a press release.
Source: Immuno-Oncology News







